ReviewHealth technology assessment (Winchester, England)2022
Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis.
Review in Health technology assessment (Winchester, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06212713 (Development and Validation of a Health Behaviour Theory-based Questionnaire to Explore the Willingness of Older Adults and Informal Caregivers to Deprescribe), which is not on this map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Development and Validation of a Health Behaviour Theory-based Questionnaire to Explore the Willingness of Older Adults and Informal Caregivers to Deprescribe
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- The views of healthcare professionals and family members on deprescribing preventive medication in people living with dementia: a qualitative systematic review.BMC geriatrics · 2026Pooled it
- A NASSS framework-guided systematic review and exploratory modelling of digital health interventions for polypharmacy management in older adults.BMC geriatrics · 2025Pooled it
- Medicine Optimisation and Deprescribing Intervention Outcomes for Older People with Dementia or Mild Cognitive Impairment: A Systematic Review.Drugs & aging · 2025Pooled it
- Pooled it
- Behavioral Determinants of Older Adults' and Caregivers' Willingness to Deprescribe: A Systematic Review.Public health nursing (Boston, Mass.)Pooled it
- Attitudes Toward Deprescribing Among Older Adults Seeking Care in the Emergency Department.Journal of the American College of Emergency Physicians open · 2026Article
- Recommendations for the management of frailty in chronic kidney disease: a consensus report.Nature reviews. Nephrology · 2026Review
- Global Trends in Deprescribing Benzodiazepine Receptor Agonists in Older Adults: A Dual-Database Bibliometric and Visual Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Evaluating the implementation of a deprescribing intervention in Swiss nursing homes: An observational study using qualitative and quantitative methods.Exploratory research in clinical and social pharmacy · 2026Article
- Functional Deprescribing: A Systems-Based Framework for Safe Medication Reduction.Integrative medicine (Encinitas, Calif.) · 2026Article
- The Environmental and Global Impact of Pharmacogenomics: Advancing Green Pharmacy Toward Sustainable and Inclusive Precision Medicine.Journal of personalized medicine · 2026Review
- Polypharmacy and potentially inappropriate prescribing in people with type 2 diabetes: An analysis of the Scottish Diabetes Research Network national diabetes cohort.Diabetic medicine : a journal of the British Diabetic Association · 2026Article
- HOPE-AO overprescribing in older adults with chronic pain: a protocol for qualitative interviews with patients and healthcare professionals.NIHR open research · 2026Article
- Article
- Understanding Undergraduate Medicines Optimisation Education and Its Importance; a Realist Evaluation.Perspectives on medical education · 2026Article
- Methods of Engaging Interest-Holders in Healthcare Evidence Syntheses: A Scoping Review.Cochrane evidence synthesis and methods · 2026Review
- [Telegeriatrics for chronic disease management through polypharmacy reduction in primary health careTelegeriatria para o controle de doenças crônicas por meio da redução da polifarmácia na atenção primária à saúde].Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Attitudes and confidence toward deprescribing: a survey among Italian general practitioners.BMC primary care · 2025Observational
- Mapping care trajectories for hospital-initiated benzodiazepine deprescribing in older adults: a multicentre qualitative study.BMC health services research · 2025Article
- GPs' decision-making behaviour in the prescription of aspirin for primary prevention in elderly individuals: a qualitative study using semistructured interviews in France.BMC primary care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTackling problematic polypharmacy requires tailoring the use of medicines to individual needs and circumstances. This may involve stopping medicines (deprescribing) but patients and clinicians report uncertainty on how best to do this. The TAILOR medication synthesis sought to help understand how best to support deprescribing in older people living with multimorbidity and polypharmacy.
objectivesWe identified two research questions: (1) what evidence exists to support the safe, effective and acceptable stopping of medication in this patient group, and (2) how, for whom and in what contexts can safe and effective tailoring of clinical decisions related to medication use work to produce desired outcomes? We thus described three objectives: (1) to undertake a robust scoping review of the literature on stopping medicines in this group to describe what is being done, where and for what effect; (2) to undertake a realist synthesis review to construct a programme theory that describes 'best practice' and helps explain the heterogeneity of deprescribing approaches; and (3) to translate findings into resources to support tailored prescribing in clinical practice. DATA SOURCES: Experienced information specialists conducted comprehensive searches in MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Web of Science, EMBASE, The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials), Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports, Google (Google Inc., Mountain View, CA, USA) and Google Scholar (targeted searches). REVIEW
methodsThe scoping review followed the five steps described by the Joanna Briggs Institute methodology for conducting a scoping review. The realist review followed the methodological and publication standards for realist reviews described by the Realist And Meta-narrative Evidence Syntheses: Evolving Standards (RAMESES) group. Patient and public involvement partners ensured that our analysis retained a patient-centred focus.
resultsOur scoping review identified 9528 abstracts: 8847 were removed at screening and 662 were removed at full-text review. This left 20 studies (published between 2009 and 2020) that examined the effectiveness, safety and acceptability of deprescribing in adults (aged ≥ 50 years) with polypharmacy (five or more prescribed medications) and multimorbidity (two or more conditions). Our analysis revealed that deprescribing under research conditions mapped well to expert guidance on the steps needed for good clinical practice. Our findings offer evidence-informed support to clinicians regarding the safety, clinician acceptability and potential effectiveness of clinical decision-making that demonstrates a structured approach to deprescribing decisions. Our realist review identified 2602 studies with 119 included in the final analysis. The analysis outlined 34 context-mechanism-outcome configurations describing the knowledge work of tailored prescribing under eight headings related to organisational, health-care professional and patient factors, and interventions to improve deprescribing. We conclude that robust tailored deprescribing requires attention to providing an enabling infrastructure, access to data, tailored explanations and trust. LIMITATIONS: Strict application of our definition of multimorbidity during the scoping review may have had an impact on the relevance of the review to clinical practice. The realist review was limited by the data (evidence) available.
conclusionsOur combined reviews recognise deprescribing as a complex intervention and provide support for the safety of structured approaches to deprescribing, but also highlight the need to integrate patient-centred and contextual factors into best practice models. FUTURE WORK: The TAILOR study has informed new funded research tackling deprescribing in sleep management, and professional education. Further research is being developed to implement tailored prescribing into routine primary care practice. STUDY REGISTRATION: This study is registered as PROSPERO CRD42018107544 and PROSPERO CRD42018104176.
fundingThis project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.